© 2006 European Society for Medical Oncology
editorial |
Transcriptional profiling of tumor biopsies in oncology trials—a ‘window’ of opportunity for evaluating new drugs in nasopharyngeal cancer?
Department of Clinical Oncology, Sir Y. K. Pao Center for Cancer, Chinese University of Hong Kong, Prince of Wales Hospital, Shatin, New Territories, Hong Kong SAR, China
*(E-mail: anthony@clo.cuhk.edu.hk)
| The first 150 words of the full text of this article appear below. |
Historically, microarray-based expression profiling of tumor tissues has been used to identify molecular signatures that can promote the precise classification and prognostication of human cancers. There is a recent move toward applying this tool in the development of targeted drugs in oncology, where transcriptional profiling of tumor samples are performed for the purpose of elucidating the mechanisms of drug action and identifying biomakers of drug response [1]. In this issue of the Annals of Oncology, Dr Soo et al. [2] report an interesting study on the pharmacodynamic evaluation of celecoxib that focused on whether it could alter global gene expression, microvessel density (MVD) and proliferation index (Ki-67) in nasopharyngeal cancer (NPC). They designed a window study where subjects with untreated NPC were given 14 days of celecoxib before undergoing curative radiotherapy. Endoscopic biopsies of primary tumor were obtained at baseline and on the 14th day
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  K. J Randall and J. R. Foster The Demonstration of Immunohistochemical Biomarkers in Methyl Methacrylate-Embedded Plucked Human Hair Follicles Toxicol Pathol, December 1, 2007; 35(7): 952 - 957. [Abstract] [Full Text] [PDF]
|
|